A Clinical and Imaging Study to Evaluate a Novel Dentifrice
NCT ID: NCT02271815
Last Updated: 2022-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
194 participants
OBSERVATIONAL
2014-10-31
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Invasive Oral Biofilm Characterization
NCT02178046
Imaging-based Assessment of Oral Biofilm and Gingival Health
NCT05470023
Evaluate Dental Plaque Benefit of a Preventive Treatment Gel
NCT03546491
A Clinical Study to Assess the Gingivitis and Plaque Effects of Various Dentifrices
NCT06140784
Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences
NCT07124533
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Imaging devices:
* Optical Coherence Tomography can be used to identify and measure inflammation of the gums and gum pockets.The results can be used to evaluate the health of the gums, and changes caused by using specific toothpastes
* Multiphoton Microscopy can be used to identify and measure bacterial plaque or biofilm in the mouth. The results can determine effects of specific toothpastes on the development and breakup of bacterial biofilm or plaque.
In the first part of this study, subjects with moderate gingival inflammation (Löe and Silness Gingival Index ≥2) and pocket depths \<4 will be randomly assigned to brush twice daily for 21 days with the test or the control dental gel. On Days 0, 7, 14, and 21, plaque levels (Quigley-Hein, Turesky Modification Plaque Index), gingival inflammation (Löe and Silness Gingival Index), and gingival bleeding (modified Sulcus Bleeding Index) will be determined by one blinded, investigator (Dr. Wilder-Smith) using standard probing techniques. In vivo Optical Coherence Tomography (OCT) and Multiphoton Microscopy (MPM) will be used for in situ imaging. The results from this study will help evaluate the effects of the test dentifrice formulation on plaque removal and maintaining gingival health.
In the second part of this study, plaque formation and removal will be quantified in subjects using ex vivo Optical Coherence Tomography (OCT) and Multiphoton Microscopy (MPM) imaging of small enamel chips mounted on a simple intra-oral retainer. In this cross-over design study, the subjects will attend the test site on 11 occasions over an 11-week period. Subjects will have an intra-oral retainer manufactured, which will be worn for a minimum of 22 hours per day and will have up to 8 sterile human enamel inserts fitted.This study will be conducted in three arms with a maximum of 44h of retainer wear during each arm, and each study arm will follow the same procedure. 2 different over-the-counter toothpastes and a water control will be used for each arm of the study, respectively. There will be a minimum of two weeks between each study arm.
The third part of this study will involve subjects with no specific oral health issues. The protocol will involve subjects wearing simple retainers for 3 periods of 2 weeks each with 5 sterilized enamel chips attached in the palate area. The study will have 3 arms using a control and 2 active toothpastes. There will be washout of 1-2 weeks between each study arm. Samples will be analyzed outside of the mouth using OCT and MPM techniques, as well as micro computer tomography (microCT), Energy Dispersive Spectroscopy (EDS) and X-Ray Photoelectron Spectroscopy (XPS). (Section 3 has been completed as of July 11, 2016)
The fourth part of this study will involve subjects with xerostomia. Subjects will wear simple removable retainers for 2 periods of 1 week each, with 5 sterilized demineralized enamel chips attached in the palate area of the retainer. Fresh enamel chips will be used for each arm of the study. After study completion, chips will be used for Scanning Electron microscopy (SEM) and microhardness measurement. We will provide custom retainers made from impressions of each subject. Upon conclusion of the study, we will analyze the effects of each toothpaste on surface enamel using scanning electron microscopy (SEM) and microhardness as well as microCT, EDS and XPS data.
In the fifth part of this study, plaque formation and removal in subjects will be quantified using the standard clinical index for plaque levels (Quigley-Hein, Turesky Modification Plaque Index). This will be determined by one blinded investigator using a periodontal probe. In addition, ex vivo Optical Coherence Tomography (OCT) and Multiphoton Microscopy (MPM) imaging of biofilm samples will be performed on plaque specimens collected using standardized technique and a 2mm curette. In this 3-arm cross-over double-blinded study, the subjects will attend the test site for up to 7 occasions over up to a 22-day period.
The sixth part of this study will involve (a) subjects with previously diagnosed gingivitis, including moderate gingival inflammation (Löe and Silness Gingival Index ≥2) and pocket depths \<4, and (b) subjects with previously diagnosed gingivitis (moderate gingival inflammation (Löe and Silness Gingival Index ≥2)) AND periodontitis including gingival bleeding, gingival inflammation, and at least four sites with probing pocket depths \>4mm. Subjects will be randomly assigned to brush twice daily for up to 6 months with the test or the control dental gel. On Days 0, 30, 90, and 180, plaque levels (Quigley-Hein, Turesky Modification Plaque Index), gingival inflammation (Löe and Silness Gingival Index), gingival bleeding (modified Sulcus Bleeding Index) and periodontal pocket depths will be determined by one blinded, investigator (Dr. Wilder-Smith) using a periodontal probe. In vivo Optical Coherence Tomography (OCT) and Multiphoton Microscopy (MPM) may be used for in situ imaging if gingival/periodontitis sites are accessible to the imaging probes. The results from this study will help evaluate the effects of the test dentifrice formulation on plaque removal and maintaining/recovering gingival/periodontal health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Hygiene
Oral Hygiene
Oral Hygiene
Oral Hygiene
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Hygiene
Oral Hygiene
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a previously diagnosed condition of gingivitis and periodontitis including gingival bleeding, gingival inflammation, plaque, and for some study sections at least four sites with probing pocket depths \> 4mm.
* Not pregnant and not lactating.
Exclusion Criteria
* Plan to receive dental treatment during the study dates.
* History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses.
* Allergies to personal care/consumer products or their ingredients.
* Less than 20 teeth (excluding third molars).
* For some studies, within six months prior to baseline, any quadrant or maintenance S/RP, and/or periodontal surgical therapy
* Diagnosed with active acquired immunodeficiency syndrome (AIDS) or Hepatitis B/C and other significant disease or disorder.
* Poorly controlled diabetes
* History of herpetic infection, recurrent aphthous ulcer, or other ulcerative diseases, abscesses, granulomas.
* History of or currently undergoing immunosuppression
* Taken antibiotics in the previous 3 months.
* Taking anti-inflammatory medications or Immunosuppressants.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Livionex Inc.
INDUSTRY
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Petra E. Wilder-Smith
Professor, Director of Dentistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Petra Wilder-Smith, DDS, DMD, PhD
Role: PRINCIPAL_INVESTIGATOR
Beckman Laser Institute, UCI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beckman Laser Institute, University of california, Irvine
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Livionex, Inc.
Identifier Type: OTHER
Identifier Source: secondary_id
20139778
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.